The New Director Of The US FDA Has Released A Report On His First 100 Days in Office, And Has Seized Illegal Electronic Cigarettes Worth Nearly 34 Million US Dollars.

On July 10th, the new FDA director in the United States, Marty Makary, issued a statement, updating the work he had accomplished leading the FDA over the past 100 days and setting out a roadmap for future goals. Among them, a key point was the fight against illegal e-cigarettes.
He said: "The products regulated by the FDA account for 20% of the total spending in the United States. Our work affects the lives of every American. In the past 100 days, we have initiated dozens of important initiatives within the scope of the FDA's various responsibilities, aiming to help provide healthier food for children and families, accelerate effective cures and treatments, and achieve the modernization of the FDA through transparency, gold standard science, and common sense."
The statement then listed dozens of key points, highlighting the ongoing work, with most of it focusing on the manufacturing of drugs and food.
Under the title "Management - Gold Standard Science and Common Sense", Makary stated that the FDA is protecting American consumers by cracking down on illegal e-cigarettes. The statement said: "In collaboration with the U.S. Customs and Border Protection Agency, nearly 34 million U.S. dollars worth of illegal, attractive to young people e-cigarette products from China were seized."

Makary also pointed out that the FDA implements artificial intelligence to assist all departments in reviewing products, which is particularly beneficial to the nicotine industry, as the industry has made almost no progress in e-cigarettes and alternative products over the years.
The statement said: "The first artificial intelligence-assisted scientific review pilot has been successfully completed, indicating that internal artificial intelligence tools can significantly reduce the time spent by reviewers on cumbersome tasks or non-productive and cumbersome work. Elsa was launched, a generative artificial intelligence tool, designed to help all FDA employees - from scientific reviewers to researchers - work more efficiently. Elsa is just the first step in FDA's grand plan to integrate artificial intelligence into institutional processes."
"The outstanding team of the FDA has achieved such accomplishments within 100 days of adhering to gold standard science, complete transparency, and common sense. I am very excited about this. This is just the beginning. We will continue to introduce various measures to promote the modernization process of the FDA," Makary said.